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Integrating viruses represent robust tools for cellular reprogramming; however, the presence of viral transgenes in
induced pluripotent stem cells (iPSCs) is deleterious because it holds the risk of insertional mutagenesis leading to
malignant transformation. Here, we combine the robustness of lentiviral reprogramming with the efficacy of Cre
recombinase protein transduction to derive iPSCs devoid of transgenes. By genome-wide analysis and targeted
differentiation towards the cardiomyocyte lineage, we show that transgene-free iPSCs are superior to iPSCs before
Cre transduction. Our study provides a simple, rapid and robust protocol for the generation of clinical-grade iPSCs
suitable for disease modeling, tissue engineering and cell replacement therapies.Introduction
Initial reports for generating induced pluripotent stem
cells (iPSCs) involved retroviruses as a mode of transgene
delivery [1]. Although retroviruses are capable of repro-
gramming somatic cells to iPSCs, the clinical applicability
of such iPSCs is limited due to the integrated transgenes
carrying the risk of insertional mutagenesis [2] and tumor
formation [3]. Moreover, continuous expression of trans-
genes in iPSCs negatively affects pluripotency [4] and
limits their differentiation potential [5]. These effects have
been shown by the inability to yield live chimeric mice
and the diminished endodermal differentiation of iPSCs
carrying transgenes [5]. Alternative approaches were ex-
plored to obtain higher efficiency with minimal genetic
modifications of the cells. Various protocols circumvent-
ing viral vectors have been published, including the use of
transposons [6], episomal plasmids [7], synthetic mRNA* Correspondence: frank.edenhofer@uni-wuerzburg.de
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unless otherwise stated.[8], microRNAs [9], Sendai virus [10] as well as protein
transduction [11-13]. iPSCs generated by these methods
contain minimal or no genetic modifications and are gen-
erally more suitable for clinical applications than cells de-
rived by virus-based protocols. However, still there is no
gold standard for an iPSC reprogramming strategy since
these non-integrating approaches exhibit limitations such
as low reprogramming efficiencies, slow reprogramming
kinetics, a narrow range of cell specificity, and poor repro-
ducibility [14,15]. In terms of robustness and efficacy,
therefore, the retroviral and lentiviral system still repre-
sents the method of choice for iPSC derivation [16].
Early attempts to improve viral-based iPSC protocols in-
cluded the use of polycistronic vectors. The core element
of those vectors is a cassette, consisting of cDNAs of the
four transcription factors, linked together via 2A self-
cleaving peptide sequences [17,18]. This strategy allows
translation of four separate polypeptides from a single
mRNA strand. Thus, instead of four viruses, a single con-
struct is sufficient to induce cellular reprogramming. This
approach decreases the risk of insertional mutagenesis.
Various biomedical applications of iPSCs will not strictly re-
quire cells completely free from genetic modifications.
Hence, a Cre-excisable lentiviral system would provide atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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free iPSC clones. The usage of polycistronic vectors harbor-
ing loxP sites allows transgene excision from iPSCs via
transient expression of Cre recombinase [19]. However, the
reprogramming efficiency using these vectors was reported
to be only 0.01% [19]. In 2009 Sommer and colleagues re-
ported an improved lentiviral vector to overcome this limi-
tation by yielding a reprogramming efficiency of 0.1 to 1.5%
[20]. Moreover, the vector could also reprogram peripheral
blood cells that are usually quite resistant towards repro-
gramming [21]. However, deletion of the loxP-flanked
transgene cassette requires introduction of Cre recombin-
ase activity. This activity has been accomplished by either
transfection of iPSCs with a Cre-encoding plasmid [19,22]
or using an adenoviral Cre construct [5,23] and subsequent
genetic identification of successfully recombined clones.
More recently, transgene-free iPSCs were obtained by ex-
cising the transgene cassette by delivery of Cre mRNA [24].
However, this protocol involves daily transfection of mRNA
for a week to perform excision. This rather inefficient and
laborious transfection and selection procedure makes Cre/
loxP-based iPSC derivation less appealing for obtaining
transgene-free iPSCs. In fact, efficient and reliable induction
of Cre recombinase activity in loxP-modified iPSCs and
subsequent selection of cleaned clones represents a road-
block for the widespread use of Cre-deletable iPSC systems.
Direct delivery of biologically active Cre protein has
been shown to be a highly efficient and robust method
for inducing Cre recombinase activity in mammalian
cells [25-28]. We reported a cell-permeable recombinant
Cre protein that was generated by fusing Cre with the
cell-penetrating peptide TAT and a nuclear localization
sequence [29]. The TAT peptide confers cell permeability
and the nuclear localization sequence targets the fusion
protein to the nucleus. TAT-Cre was used for site-specific
recombination in human embryonic stem cells (ESCs) with
more than 90% recombination efficiency [27]. Here, we
show rapid derivation of transgene-free human iPSC clones
by combining direct delivery of biologically active TAT-Cre
protein with robust reprogramming by a lentiviral polycis-
tronic vector. We demonstrate that transgene deletion ren-
ders iPSCs that resemble more human ESCs with respect
to gene expression than transgene-harboring cells before
deletion. Moreover, we show a strong enhancement of dif-
ferentiation towards the cardiac lineage in transgene-free
iPSCs as compared with loxP-modified iPSCs.
Materials and methods
Reprogramming of human fibroblasts and
characterization of iPSCs
The human fibroblasts used in this study were obtained
from a skin punch biopsy of a 24-year-old male after
obtaining informed consent and ethical clearance by the
ethics committee of the University of Würzburg, Germany(ethical report number 96/11, dated 10 June 2011). Human
fibroblasts were infected with the Human STEMCCA
Cre-Excisable constitutive polycistronic (OKSM) lentiviral
vector [22] and were seeded on irradiated mouse embry-
onic fibroblasts in a reprogramming medium consisting of
Dulbecco’s modified Eagle’s medium/F12 (Sigma-Aldrich,
St. Louis, MO, USA) with 20% KnockOut Serum Replace-
ment (Invitrogen, Carlsbad, CA, USA), 1 mM non-animal
L-glutamine (Sigma-Aldrich), 0.1 mM β-mercaptoethanol
(Sigma-Aldrich), 1% non-essential amino acids (Invitro-
gen), and 10 ng/ml basic fibroblast growth factor (Invi-
trogen). After 3 weeks, iPSC-like colonies were picked,
expanded on matrigel-coated dishes and characterized
for the pluripotency markers Oct4 (Santacruz Biotech-
nology, Finnell Street Dallas, Texas 75220 USA) and
SSEA-4 (Millipore, Temecula, CA, USA) antibodies.
TAT-Cre treatment of human iPSCs
Human iPSCs were maintained on matrigel-coated dishes
in mTeSR™1 (STEMCELL Technologies, Temecula, CA,
USA) or PluriSTEM™ (EMD Millipore, Vancouver, BC,
Canada) medium. Human iPSC colonies were treated with
alphazyme (1 ml/well in a six-well plate; PAA, Linz, Austria)
for 5 to 10 minutes to obtain single cells. Then 100,000 to
200,000 cells were seeded in each well of a six-well plate
having mTeSR™1 or PluriSTEM™medium with 10 μM Rock
inhibitor (Y27632; Sigma-Aldrich) to prevent the cell apop-
tosis. Twenty-four hours later, the medium was changed to
mTeSR™1 or PluriSTEM™ containing TAT–Cre (catalogue
number SCR508; EMD Millipore) with different concentra-
tions of 0.5 μM, 1 μM and 2 μM. Cells were incubated with
TAT-Cre recombinant protein for 5 hours. Cells were
grown for 1 week and colonies were expanded either mono-
clonally or polyclonally, and then polymerase chain reaction
(PCR) was performed to assess transgene deletion.
Transgene-deleted clones were expanded and characterized
further by immunostaining and differentiation.
Excision of the reprogramming cassette
To confirm the transgene deletion, genomic DNA from
TAT-Cre-treated subclones were isolated and PCR was
performed with the following conditions: 95°C for 2 mi-
nutes; followed by 34 cycles of 94°C for 30 seconds, 60°C
for 30 seconds, and 72°C for 45 seconds; followed by a
single cycle of 72°C for 5 minutes using the primers
WPRE forward, ATCATGCTATTGCTTCCCGTATGGC
and WPRE reverse, GGAGATCCGACTCGTCTGAGG,
and β-actin forward, GGCTACAGCTTCACCACCAC
and β-actin reverse, CCACCTTCCAGCAGATGTGG.
Immunostaining
For iPSC characterization, immunostaining was per-
formed using Oct4 (1:100; Santacruz Biotechnology) and
SSEA-4 (1:200; Millipore) antibodies. Briefly, cells were
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4% paraformaldehyde for 15 minutes and permeabilized in
PBS containing 0.1% Triton X-100 and 5% fetal calf serum
for 30 minutes. Cells were then incubated overnight with
the Oct4 and SSEA-4 antibodies. Next day, secondary anti-
bodies Alexa 488 and Alexa 555 (1:1000; Life Technologies,
Carlsbad, CA, USA) were used to detect and visualize the
primary antibodies. All antibodies were diluted in blocking
solution. Micrographs were taken with an Axiovert 200 M
microscope (Carl Zeiss, Oberkochen, Badenwürttemberg,
Germany). The above immunostaining protocol was also
performed to characterize cardiomyocytes using cardiac
Troponin T (cTNT, 1:100; Abcam, Cambridge, England)
and α-actinin (1:200; Sigma-Aldrich) as a primary antibody
and Alexa 488 as a secondary antibody.
Teratoma formation and karyotype analysis
Pluripotency was tested by injection of the test cell popu-
lation into the testes of immune-deficient NOD/SCID
mice. Then 0.5 × 106 to 5 × 106 cells were injected using a
pulled glass capillary pipette that was advanced via the ef-
ferent ducts through the rete testis into the interstitial
space of the testis. Animals were euthanized when palp-
able tumors were present or at 4 months after injection,
whichever came first. The teratomas were fixed in 10%
neutral buffered formalin, dehydrated (graded alcohols),
cleared (xylene) and embedded with paraffin wax (forma-
lin fixed paraffin embedded). Then 5 μm sections were
cut, floated on a water bath and picked up on positively
charged slides (Probe On Plus). Sections were then depar-
affinized in three changes of xylene, rehydrated in a series
of graded alcohols (100% × 2, 70% × 2, 30% × 2, distilled
H2O × 2) and hematoxylin and eosin staining was per-
formed. Karyotype analysis was performed on 20 G-
banded metaphase cells for TAT-Cre excised human iPSC
clone at p13 by Cell Line Genetics (Madiso, WI, USA).
Gene expression analysis
RNA was isolated using the RNeasy-Kit (Qiagen, Hilden,
Germany). mRNA transcription levels were evaluated
using the Human HT-12 array (version 4, revision 2;
Qiagen, Hilden, Germany), which consists of 47,323
probes and described mRNA features. All samples were
processed at least in duplicate to reduce signals arising
from processing artifacts. Data processing was per-
formed using the GenomeStudio suite version 2011.1
and the Gene expression module version 1.9.4 (both Illu-
mina Inc., San Diego, CA, USA). Gene expression data
analysis was carried out with the R and Bioconductor
packages, and their intensities were quantile normalized.
The differentially expressed genes were determined by ap-
plying the empirical Bayes test statistics, and the Benja-
mini–Hochberg false discovery method was used for
multiple testing correction. Genes with fold-change >2and P ≤ 0.5 were considered differentially expressed and
were used for subsequent analysis. The data discussed in
this publication have been deposited in the National Cen-
ter for Biotechnology Information Gene Expression
Omnibus [GEO:GSE55725].
Generation of the Cre reporter human iPSC line
Human iPSC line del-AR1034ZIMA (del-ARiPS) clone
1.4 was treated with alfazyme to obtain a single-cell sus-
pension. Then 200,000 cells were seeded in one well of a
six-well plate in mTeSR™1 medium with 10 μM Rock in-
hibitor. On the next day, cells were infected with lenti-
virus containing EF1α-Cre reporter–puromycin construct
(modified from original construct [30] by replacing CMV
promoter by EF1α promoter). Forty-eight hours later,
the medium was changed to mTeSR™1 with puromycin
(1 μg/ml) for 5 days to obtain colonies with stably inte-
grated Cre reporter construct.
Cardiomyocyte differentiation of human iPSCs
Human iPSCs were maintained on matrigel-coated plates
in mTeSR™1 medium until they reached 80% confluency.
Cardiac differentiation was induced by Activin A (5 ng/ml),
BMP4 (25 ng/ml) and Chir99021 (5 μM) in RPMI 1640
medium containing B27 and 2 mM glutamine as a basal
medium for 3 days. From day 4, cells were kept in basal
medium containing Wnt inhibitor XAV939 for 5 days
followed by further culture in basal medium.
Flow cytometry
Cells (1 × 106) were trypsinized and fixed with 4% para-
formaldehyde for 10 minutes. Cells were then washed
with PBS, permeabilized in PBS containing 0.1% Triton
X-100 and 5% fetal calf serum for 30 minutes and incu-
bated for 2 hours with cTNT antibody (1:100; Abcam).
No antibody was taken as a negative control. Cells were
then washed once with PBS containing 0.1% Tween-20
and resuspended in PBS containing 0.1% Triton-X 100
and 5% fetal calf serum and secondary antibody Alexa
488 anti-mouse IgG (1:1,000; Life Technologies) for
1 hour in the dark. Finally, cells were washed again with
PBS containing 0.1% Tween-20 and measured for FACS
analysis. Analysis was performed by the Flow Jo program.
Results
Overview of generation of transgene-free human iPSCs
with TAT-Cre application
Previous studies have shown successful derivation of
transgene-free iPSCs by excising a loxP-flanked trans-
gene cassette with Cre plasmid [19], Adeno-Cre [5,23]
or Cre mRNA [24]. We aimed at improving this ap-
proach by employing Cre protein transduction to en-
hance the efficiency as well as to accelerate the process
of obtaining transgene-free iPSCs. Our protocol does
Figure 1 Scheme of induced pluripotent stem cell generation and subsequent Cre protein transduction to obtain transgene-free
induced pluripotent stem cells. (A) Reprogramming of human fibroblasts to induced pluripotent stem cells (iPSCs) via lentiviral vector
STEMCCA. (B) Schematic representation of TAT-Cre treatment to obtain transgene-free iPSCs. (C) Schematic representation of the genomic
locus before (top) and after (bottom) Cre-mediated recombination. LTR, long terminal repeat; PCR, polymerase chain reaction.
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(see schematic overview in Figure 1). To generate hu-
man iPSCs we utilized the lentiviral vector STEMCCA,
which was shown to be more efficient [20] than earlier
Cre-excisable lentiviral vectors [19]. We infected human
dermal fibroblasts and obtained the AR1034ZIMA loxP-
modified iPSC line (fl-ARiPS). As described in the
scheme, we treated a single cell suspension of fl-ARiPS
cells with a single application of TAT-Cre recombinant
protein. TAT-Cre-treated cells were expanded either
monoclonally or polyclonally to yield transgene-excised
iPSCs ready for further analyses (Figure 1B). For the
confirmation of transgene excision, PCR against the viral
WPRE element was used (Figure 1C).
Assessment of TAT-Cre-mediated transgene deletion
efficiency
First, we used Cre protein transduction conditions that
we elaborated for Cre-mediated excision in human ESCs
cultivated on mouse feeder cells [27]. Moreover, to make
it practically more feasible we adopted our iPSC lines to
feeder-free conditions, which we assumed to result in
higher transgene deletion efficiency with a lower concen-
tration of TAT-Cre. In particular, we prepared a single cell
suspension of fl-ARiPSCs by treating them with alfazyme
and seeded them on matrigel-coated plates. Twenty-four
hours later, cells were treated with different concentrations
of TAT-Cre for 1 to 5 hours. TAT-Cre-treated fl-ARiPS
monoclones were expanded and analyzed for transgenedeletion. All three monoclones analyzed that were treated
with 2 μM TAT-Cre showed excision of the transgene,
while in the case of 0.5 and 1 μM TAT-Cre treatment
we observed one and two deleted clones, respectively
(Figure 2A). To explore the possibility of deletion and
subsequent polyclonal cell expansion, we treated the loxP-
modified iPSCs with 0.5, 1 and 2 μM TAT-Cre for 5 hours
and expanded them polyclonally. Genomic PCR analysis
revealed a faint band in the cases of 0.5 and 1 μM, and no
band was observed after treatment with 2 μM TAT-Cre,
indicating a high excision efficiency that was consistent
with the monoclonal analysis (Figure 2B) and previously
reported results employing human ESCs [27]. In order to
validate the PCR results we mixed genomic DNA from
loxP-modified and transgene-deleted iPSC clones in a
standardized manner representing corresponding deletion
efficiencies. PCR analysis of this dilution series yielded a
faint band even in the case of a 99% mixture, while no
band was observed with 100% deleted DNA (Figure 2C).
Protein transduction was repeated with seven monoclones
treated with 1.5, 3 and 6 μM TAT-Cre in each case. As
listed in Figure 2D, all clones analyzed showed the dele-
tion of transgenes. Increasing concentrations of TAT-Cre
beyond 3 μM resulted in significant cell death and affected
the recovery of iPSC colonies after the treatment (data
not shown). Upon using higher concentrations of TAT-
Cre, excessive cell death was prevented by shortening the
time duration of TAT-Cre treatment (5 μM TAT-Cre for
1 hour) without compromising the recombination
Figure 2 Assessment of TAT-Cre-mediated transgene deletion efficiency. (A) Genomic polymerase chain reaction (PCR) for the confirmation
of transgene deletion. Three individual clones were treated with 0.5, 1 or 2 μM TAT-Cre for 5 hours and PCR was performed using primers against
WPRE and β-actin. F, AR1034ZIMA loxP-modified iPSC line clone 1 (fl-ARiPSC); NC, negative (water) control; WPRE, viral element; BA, β-actin.
(B) Genomic PCR for the confirmation of transgene deletion in a polyclonal population. fl-ARiPSCs were treated with 0.5, 1 or 2 μM TAT-Cre for
5 hours. Cells were expanded polyclonally and PCR was performed using primers against WPRE and β-actin. (C) Validation of genomic PCR
analysis. Genomic DNA from loxP-modified and transgene deleted cells were mixed to create defined dilutions as given. (D) Quantification of
transgene-deleted clones using different concentrations and time duration of TAT-Cre. (E) ARiPS-Cre reporter cell line was treated with 2 μM
Cre protein to validate recombination efficiency. Cre-mediated recombination induced the expression of green fluorescence protein (EGFP), by
deleting the loxP-flanking RFP gene. Scale bar: 120 μm.
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12 clones tested (Figure 2D). To further confirm the effi-
ciency of TAT-Cre, we monitored the recombination
event by integrating a double fluorescence Cre reporter
cassette through lentiviral transduction of fl-ARiPSC.
We observed more than 95% of cells showing GFP ex-
pression with 2 μM TAT-Cre for 5 hours (Figure 2E),
confirming the high recombination efficiency deter-
mined by PCR analyses.
Characterization of transgene-free iPSCs
To assess the pluripotency status of excised del-ARiPS
clones, cells were expanded until passage 15 and stained
with pluripotency-associated markers Oct4 and SSEA-4.
Cells stained positive for both nuclear Oct4 and cell
surface marker SSEA-4 (Figure 3A). Furthermore, we
performed genome-wide gene expression profiling on
del-ARiPS cells and fl-ARiPS cells by microarray ana-
lysis. The gene expression datasets were subjected to the
recently published bioinformatics assay PluriTest [31] to
assess the pluripotency status of reprogrammed cells.
According to this analysis, both fl-ARiPS cells and del-
ARiPS cells cluster with human ESC line HES I3 in thered-colored background, indicating pluripotency, while
fibroblasts are located in the blue region, confirming
their nonpluripotent nature (Figure 3B). Notably, del-
ARiPS cells appear slightly more shifted to the HES I3
cells as compared with fl-ARiPS cells. Expression profil-
ing of pluripotency-associated genes Oct4, Sox2 and
Rex1 as well as fibroblast genes Thy1 and Col5a2
showed similar expression pattern across the iPSCs and
human ESCs. Again del-ARiPS cells appear more similar
to HES I3 than fl-ARiPS cells (Figure 3C). In fact, there
are 63 differentially expressed genes between HES I3
and del-ARiPS cells as compared with more than 130
genes in the case of the parental fl-ARiPS clone (Figure 3D).
Furthermore, excised clone could give rise to teratoma
consisting of all three germ layers, confirming its in vivo
differentiation potential (Figure 3E), and showed no
chromosomal aberrations as judged by karyotype analysis
(Figure 3F).
Improved cardiac differentiation potential of
transgene-free iPSCs
To explore whether the deletion of transgenes not only
results in genome-wide transcriptional differences but
Figure 3 Characterization of transgene-free induced pluripotent stem cells. (A) Pluripotency analysis of transgene-excised clones. del-
ARiPSCs stain positive for pluripotency-associated markers Oct4 and SSEA-4. Scale bar: 40 μm. (B) PluriTest analysis of HES I3, fl-ARiPSC, del-ARiPSC
cells and parental fibroblasts to assess pluripotency induction. Cells are distributed based on pluripotency and novelty scores, as indicated by
color density background. Red, pluripotency; blue, nonpluripotency. (C) Heat-map representation of pluripotency and fibroblast-specific markers.
Expression of pluripotency-associated markers Oct4, Sox2 and Rex1 and fibroblast specific markers Thy1 and Col5a2 in induced pluripotent stem
cells (iPSCs) and human embryonic stem cells (ESCs) used for this study. (D) Venn diagram showing differentially expressed genes. Comparison
of differentially expressed genes amongst HES I3, fl-ARiPSC and del-ARiPSC cells. (E) Histological analysis of teratoma analysis of excised clone.
Teratoma analysis after injection of the excised clone into SCID mice showed formation of all three germ layers: ectoderm (primitive neuroepithelium),
mesoderm (cartilage, muscle) and endoderm (glands). (F) Karyotype analysis of transgene-excised clone. Cytogenetic analysis on G-banded metaphase
cells from excised clone (p13) and all 20 cells demonstrated a normal male karyotype. HES I3, human ESC I3 line; fl-ARiPS, fl-ARiPS iPSC clone 1;
del-ARiPS, transgene-free daughter clones of ARIPS iPSC clone 1.
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tiation potential by differentiation into the cardiac lineage.
To achieve cardiac differentiation, we modified the protocol
described by Carpenter and colleagues [32] with the inclu-
sion of modulation of the Wnt signaling pathway using
Chir99021 to enhance cardiac differentiation. We employed
this protocol for the cardiac differentiation of fl-ARiPS cells
and a polyclonal TAT-Cre-treated daughter cell population
(2 μM TAT-Cre for 5 hours) (Figure 4A,B). We decided
to perform polyclonal expansion in order to reduce the
time duration of the entire procedure and to check
whether it is possible to see the overall enhancement in
differentiation capacity of a polyclonal TAT-Cre-treated
population. Indeed, flow cytometry analysis using cTNT
as a cardiomyocyte-specific marker indicates a strongly in-
creased differentiation capability of del-ARiPS cells. More
than 55% of differentiated del-ARiPS cells are cTNT-
positive, whereas only 37% of the parental fl-ARiPSC cells
stained positive for cTNT (Figure 4C).
Discussion
In this study we demonstrate an efficient way of obtaining
iPSCs with minimal genetic modifications by combining
the widely applied and robust lentiviral reprogrammingapproach with the highly efficient and less invasive TAT-
Cre-mediated transgene deletion. Earlier studies have
reported the deletion of transgenes by delivering Cre as a
plasmid, as Adeno-Cre, or by mRNA transfection [5,19,22-24].
The protocol elaborated by Soldner and colleagues yielded
only 16 transgene-deleted clones out of 180 analyzed after
transfecting iPSCs with a Cre-encoding plasmid and sub-
sequent selection either with green fluorescent protein
fluorescence or puromycin [19]. The relatively low effi-
ciency might be due to the transient transfection of Cre,
which is limiting intracellular DNA recombinase activity.
Sommer and colleagues and Somers and colleagues used
Adeno-Cre and Cre-IRES-Puro constructs respectively to
achieve higher excision efficiencies [5,22]. A more recent
study by Awe and colleagues demonstrate transgene exci-
sion in iPSC clones with putative clinical grade status
using Adeno-Cre-mediated transgene deletion. During
their transgene excision analysis the authors obtained only
one transgene-excised subclone out of six Adeno-Cre-
treated clones [23]. Furthermore, deletion approaches
using Cre plasmids or Adeno-Cre constructs require
transfection and subsequent selection of cells with Cre re-
combinase activity either by flow cytometry sorting or by
antibiotic selection. Such relatively complicated steps are
Figure 4 Improved cardiac differentiation potential of transgene-free induced pluripotent stem cells. (A) Genomic polymerase chain
reaction (PCR) for the confirmation of transgene deletion. fl-ARiPS clone 1 was treated with 2 μM TAT-Cre for 5 hours and PCR was performed
using primers against WPRE and β-actin (BA). (B) Cardiomyocyte differentiation of iPSCs. fl-ARiPS clone 1 and its TAT-Cre-treated polyclonal cell
progeny were differentiated towards cardiomyocyte lineage using cardio-inductive medium. Cells were stained with α-actinin antibody at day 15.
Scale bar: 40 μm. (C) Flow cytometry analysis of cardiac-specific troponin T (cTNT) staining at day 15 of cardiac differentiation. Cardiac differentiation
showed an increase from 37 to 56% cTNT-positive cardiomyocytes in the case of TAT-Cre-treated cell populations. The experiment was repeated twice
with similar results.
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[33]. Moreover, there is the possibility that Cre-encoding
plasmids or viral constructs integrate into the genome
[34]. More recently, the group of George Daley has re-
ported transgene excision by transfecting loxP-modified
iPSC with Cre-encoding mRNA. Notably, this procedure
involves daily transfections of Cre mRNA for 4 hours up
to 7 days, which again represents a complicated and
stressful procedure for the cells. The protocol developed
in our study, in contrast, requires just a single application
of TAT-Cre recombinant protein for 5 hours due to its
high recombination efficiency. By this, the use of TAT-
Cre accelerates the process of obtaining transgene-free
iPSCs with minimal technical complexity. During our ana-
lysis, transgene-free iPSCs remain pluripotent. Moreover,
microarray analysis indicates enhancement in the quality
of iPSCs, as transgene-excised iPSCs are more similar to
human ESCs with respect to gene expression profiling,
confirming previous studies [19]. In fact, transgene-free
iPSCs exhibit an improved differentiation potential [5].
In our study, we show enhanced cardiac differentiation
of TAT-Cre-treated polyclonal iPSCs. By this we show an
improvement in differentiation capacity of a polyclonal
cell population after the removal of transgenes with Cre-mediated recombination. This makes TAT-Cre protein an
attractive tool to obtain transgene-free iPSCs even in a
polyclonal manner as recently suggested [35], circum-
venting the laborious selection procedure of transgene-
excised clones. In conclusion, our study provides a simple,
rapid and robust protocol for the generation of superior
transgene-free iPSCs suitable for disease modeling, drug
and toxicity screening, as well as cell replacement therapies.Conclusions
In summary, our study outlines efficient derivation of
factor-free human iPSC lines by combinatorial use of the
robust lentivirus human STEMCCA vector and highly
efficient TAT-Cre protein transduction. We have shown
enhanced quality of transgene-free iPSCs using micro-
array analysis and cardiac differentiation. Moreover, we
show polyclonal expansion of transgene-deleted clones
that circumvents laborious selection procedures and
time-consuming analysis of subclones.
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